S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

Compare Stocks

Date Range: 

 Adverum BiotechnologiesTscan TherapeuticsAchilles TherapeuticsAptose BiosciencesINmune Bio
SymbolNASDAQ:ADVMNASDAQ:TCRXNASDAQ:ACHLNASDAQ:APTONASDAQ:INMB
Price Information
Current Price$2.23$7.90$6.95$2.51$20.14
50-Day Moving Average$2.39$9.31$6.28$2.74$18.99
52-Week Low$2.07$6.06$5.45$2.32$7.28
52-Week High$14.79$14.71$18.95$7.27$30.37
MarketRank™
Overall Score2.42.22.02.12.2
Analysis Score4.03.53.33.53.5
Community Score4.15.05.04.75.0
Dividend Score0.00.00.00.00.0
Ownership Score2.51.70.82.52.5
Earnings & Valuation Score1.30.60.60.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$6.43$21.67$20.80$10.60$29.67
% Upside from Price Target188.28% upside174.26% upside199.28% upside322.31% upside47.30% upside
Trade Information
Market Cap$218.82 million$189.33 million$282.32 million$223.26 million$359.34 million
Beta1.15N/AN/A1.732.78
Average Volume1,927,318108,928107,4892,189,636367,782
Sales & Book Value
Annual Revenue$250,000.00$1.09 millionN/AN/A$10,000.00
Price / Sales875.28173.70N/AN/A35,933.79
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.46 per shareN/AN/A$1.34 per share$2.88 per share
Price / Book0.50N/AN/A6.99
Profitability
Net Income$-117,510,000.00N/A$-33,200,000.00$-55,240,000.00$-12,100,000.00
EPS($1.38)N/AN/A($0.67)($1.01)
Trailing P/E RatioN/A0.000.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-32.65%N/AN/A-50.60%-40.98%
Return on Assets (ROA)-27.94%N/AN/A-47.75%-36.43%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.03%N/A0.33%
Current Ratio18.82%5.34%17.21%13.67%14.74%
Quick Ratio18.82%N/A17.21%13.67%14.74%
Ownership Information
Institutional Ownership Percentage80.69%N/A46.24%53.06%9.76%
Insider Ownership Percentage12.40%N/AN/A8.41%53.90%
Miscellaneous
Employees16761153315
Shares Outstanding98.13 million23.97 million40.62 million88.95 million17.84 million
Next Earnings Date11/4/2021 (Estimated)11/18/2021 (Estimated)N/A11/9/2021 (Estimated)11/4/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
10 Best Micro-Cap Stocks to Invest In10 Best Micro-Cap Stocks to Invest In
finance.yahoo.com - September 23 at 12:51 PM
Inmune Bio Stock Flashes Robust RS RatingInmune Bio Stock Flashes Robust RS Rating
finance.yahoo.com - September 22 at 8:23 PM
INmune Bio, Inc. Announces Participation at Upcoming Investor ConferencesINmune Bio, Inc. Announces Participation at Upcoming Investor Conferences
finance.yahoo.com - September 20 at 5:19 PM
INmune Bio, Inc.(INMB)INmune Bio, Inc.(INMB)
fool.com - September 15 at 8:07 PM
After A 131.19% Jump This Year Is INmune Bio Inc. (NASDAQ:INMB) A Better Buy Than Others?After A 131.19% Jump This Year Is INmune Bio Inc. (NASDAQ:INMB) A Better Buy Than Others?
marketingsentinel.com - September 9 at 10:15 AM
FY2023 EPS Estimates for INmune Bio, Inc. Decreased by Analyst (NASDAQ:INMB)FY2023 EPS Estimates for INmune Bio, Inc. Decreased by Analyst (NASDAQ:INMB)
americanbankingnews.com - September 9 at 7:22 AM
INmune Bio Inc. (NASDAQ: INMB) Is The Among Hot Stock Right NowINmune Bio Inc. (NASDAQ: INMB) Is The Among Hot Stock Right Now
stocksregister.com - September 8 at 2:14 PM
INmune Bio (NASDAQ:INMB) Hits New 52-Week High Following Analyst UpgradeINmune Bio (NASDAQ:INMB) Hits New 52-Week High Following Analyst Upgrade
americanbankingnews.com - September 7 at 11:12 AM
INmune Bio (NASDAQ:INMB) PT Raised to $32.00 at B. RileyINmune Bio (NASDAQ:INMB) PT Raised to $32.00 at B. Riley
americanbankingnews.com - September 7 at 10:38 AM
INmune Bio, Inc. (NASDAQ:INMB) Expected to Post Earnings of -$0.43 Per ShareINmune Bio, Inc. (NASDAQ:INMB) Expected to Post Earnings of -$0.43 Per Share
americanbankingnews.com - September 6 at 1:14 PM
INmune Bio Stock Rises As Small-Cap Shows Promise In Alzheimers DiseaseINmune Bio Stock Rises As Small-Cap Shows Promise In Alzheimer's Disease
finance.yahoo.com - September 2 at 9:08 PM
Thinking Of Selling INmune Bio Inc. (NASDAQ: INMB) Stock? Check This Out FirstThinking Of Selling INmune Bio Inc. (NASDAQ: INMB) Stock? Check This Out First
stocksregister.com - September 2 at 3:57 PM
INmune Bio Stock Pops As Small-Cap Shows Promise In Alzheimers DiseaseINmune Bio Stock Pops As Small-Cap Shows Promise In Alzheimer's Disease
finance.yahoo.com - September 2 at 3:57 PM
INmune (INMB) Announces Positive Data for its AD CandidateINmune (INMB) Announces Positive Data for its AD Candidate
finance.yahoo.com - September 2 at 3:57 PM
Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and ...Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and ...
apnews.com - September 2 at 4:25 AM
Why Are Shares Of INmune Bio Trading Higher Wednesday Afternoon?Why Are Shares Of INmune Bio Trading Higher Wednesday Afternoon?
markets.businessinsider.com - September 1 at 6:23 PM
INmune Bio Reports Positive Results From Early-Stage Trial Of Alzheimers Treatment; Shares Jump 14%INmune Bio Reports Positive Results From Early-Stage Trial Of Alzheimer's Treatment; Shares Jump 14%
nasdaq.com - September 1 at 6:23 PM
Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of RemyelinationAlzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination
finance.yahoo.com - September 1 at 6:23 PM
INmune Bio (NASDAQ:INMB) Reaches New 12-Month High at $31.00INmune Bio (NASDAQ:INMB) Reaches New 12-Month High at $31.00
americanbankingnews.com - September 1 at 5:14 PM
INmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer TrialINmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer Trial
finance.yahoo.com - August 26 at 4:42 PM
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its ...INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its ...
apnews.com - August 25 at 5:32 PM
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK CellsINmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells
finance.yahoo.com - August 25 at 5:32 PM
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth ConferenceINmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
finance.yahoo.com - August 18 at 5:17 AM
INmune Bio Inc. (NASDAQ: INMB) Is Down -24.98% In A Month. Could There Be Any Hope That It Will Rise Soon?INmune Bio Inc. (NASDAQ: INMB) Is Down -24.98% In A Month. Could There Be Any Hope That It Will Rise Soon?
marketingsentinel.com - August 14 at 3:37 PM
INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology ConferenceINmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference
finance.yahoo.com - August 5 at 1:06 PM
DateCompanyBrokerageAction
9/7/2021INmune BioB. Riley
Boost Price Target
8/13/2021Tscan TherapeuticsCowen
Initiated Coverage
8/10/2021Tscan TherapeuticsBarclays
Initiated Coverage
8/10/2021Tscan TherapeuticsJefferies Financial Group
Initiated Coverage
8/10/2021Tscan TherapeuticsMorgan Stanley
Initiated Coverage
8/10/2021Achilles TherapeuticsPiper Sandler
Lower Price Target
7/30/2021Adverum BiotechnologiesRoyal Bank of Canada
Reiterated Rating
7/23/2021Adverum BiotechnologiesThe Goldman Sachs Group
Downgrade
7/23/2021Adverum BiotechnologiesSVB Leerink
Lower Price Target
7/23/2021Adverum BiotechnologiesChardan Capital
Lower Price Target
7/23/2021Adverum BiotechnologiesCantor Fitzgerald
Downgrade
7/14/2021INmune BioB. Riley
Reiterated Rating
7/7/2021Achilles TherapeuticsChardan Capital
Reiterated Rating
7/7/2021INmune BioMaxim Group
Boost Price Target
7/5/2021Aptose BiosciencesPiper Sandler
Lower Price Target
7/1/2021Adverum BiotechnologiesChardan Capital
Reiterated Rating
5/10/2021Adverum BiotechnologiesSVB Leerink
Reiterated Rating
5/5/2021Adverum BiotechnologiesRoyal Bank of Canada
Reiterated Rating
5/5/2021Adverum BiotechnologiesTruist Securities
Reiterated Rating
5/5/2021Adverum BiotechnologiesChardan Capital
Reiterated Rating
5/3/2021Adverum BiotechnologiesSVB Leerink
Downgrade
5/3/2021Achilles TherapeuticsJPMorgan Chase & Co.
Initiated Coverage
4/29/2021Adverum BiotechnologiesLifesci Capital
Downgrade
4/29/2021Adverum BiotechnologiesChardan Capital
Downgrade
4/29/2021Adverum BiotechnologiesTruist Securities
Downgrade
4/29/2021Adverum BiotechnologiesTruist
Downgrade
4/29/2021Adverum BiotechnologiesSVB Leerink
Lower Price Target
4/29/2021Adverum BiotechnologiesRoyal Bank of Canada
Downgrade
4/27/2021INmune BioB. Riley
Initiated Coverage
4/26/2021Achilles TherapeuticsJPMorgan Chase & Co.
Initiated Coverage
4/26/2021Achilles TherapeuticsChardan Capital
Initiated Coverage
4/26/2021Achilles TherapeuticsPiper Sandler
Initiated Coverage
4/26/2021Achilles TherapeuticsOppenheimer
Initiated Coverage
4/26/2021Achilles TherapeuticsBank of America
Initiated Coverage
4/21/2021INmune BioB. Riley
Reiterated Rating
3/24/2021Aptose BiosciencesOppenheimer
Boost Price Target
3/2/2021Adverum BiotechnologiesCantor Fitzgerald
Reiterated Rating
2/22/2021Aptose BiosciencesJonestrading
Initiated Coverage
2/9/2021INmune BioMaxim Group
Reiterated Rating
1/22/2021INmune BioMaxim Group
Boost Price Target
12/15/2020Adverum BiotechnologiesUBS Group
Initiated Coverage
11/12/2020Adverum BiotechnologiesRaymond James
Upgrade
11/9/2020INmune BioHC Wainwright
Lower Price Target
11/5/2020Adverum BiotechnologiesLifesci Capital
Reiterated Rating
10/20/2020Aptose BiosciencesCanaccord Genuity
Reiterated Rating
10/19/2020Aptose BiosciencesCantor Fitzgerald
Initiated Coverage
9/22/2020Aptose BiosciencesAlliance Global Partners
Initiated Coverage
9/1/2020INmune BioBTIG Research
Initiated Coverage
8/26/2020Adverum BiotechnologiesRaymond James
Reiterated Rating
8/11/2020Adverum BiotechnologiesSVB Leerink
Boost Price Target
8/10/2020Adverum BiotechnologiesPiper Sandler
Boost Price Target
8/6/2020INmune BioHC Wainwright
Reiterated Rating
7/15/2020INmune BioHC Wainwright
Boost Price Target
7/14/2020INmune BioRoth Capital
Boost Price Target
7/8/2020Adverum BiotechnologiesCantor Fitzgerald
Boost Price Target
6/23/2020Aptose BiosciencesPiper Sandler
Reiterated Rating
6/14/2020Aptose BiosciencesOppenheimer
Initiated Coverage
6/12/2020Aptose BiosciencesMaxim Group
Initiated Coverage
6/12/2020Aptose BiosciencesHC Wainwright
Reiterated Rating
5/16/2020INmune BioMaxim Group
Initiated Coverage
5/15/2020INmune BioHC Wainwright
Reiterated Rating
4/27/2020Aptose BiosciencesHC Wainwright
Reiterated Rating
4/22/2020INmune BioMaxim Group
Reiterated Rating
3/13/2020INmune BioMaxim Group
Reiterated Rating
3/12/2020INmune BioHC Wainwright
Lower Price Target
3/4/2020Aptose BiosciencesCanaccord Genuity
Reiterated Rating
2/20/2020Aptose BiosciencesMaxim Group
Initiated Coverage
2/6/2020Aptose BiosciencesHC Wainwright
Boost Price Target
1/9/2020Aptose BiosciencesPiper Sandler
Initiated Coverage
12/19/2019INmune BioRoth Capital
Initiated Coverage
11/11/2019INmune BioHC Wainwright
Reiterated Rating
9/13/2019INmune BioMaxim Group
Set Price Target
9/12/2019INmune BioHC Wainwright
Reiterated Rating
8/21/2019INmune BioHC Wainwright
Initiated Coverage
8/14/2019INmune BioMaxim Group
Reiterated Rating
8/7/2019Aptose BiosciencesHC Wainwright
Lower Price Target
6/10/2019INmune BioMaxim Group
Set Price Target
5/23/2019Aptose BiosciencesRoth Capital
Reiterated Rating
5/16/2019INmune BioMaxim Group
Set Price Target
4/2/2019Aptose BiosciencesHC Wainwright
Set Price Target
3/22/2019Aptose BiosciencesHC Wainwright
Set Price Target
3/1/2019Aptose BiosciencesRoyal Bank of Canada
Initiated Coverage
1/25/2019Aptose BiosciencesCitigroup
Initiated Coverage
1/24/2019Aptose BiosciencesOppenheimer
Initiated Coverage
12/13/2018Aptose BiosciencesHC Wainwright
Set Price Target
12/12/2018Aptose BiosciencesRoth Capital
Reiterated Rating
12/3/2018Aptose BiosciencesHC Wainwright
Set Price Target
(Data available from 9/25/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.